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LYMPHOID NEOPLASIA
Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic
leukemia cells
Esther Hulleman,1 Karin M. Kazemier,1 Amy Holleman,1 David J. VanderWeele,2 Charles M. Rudin,2
Mathilde J. C. Broekhuis,1 William E. Evans,3 Rob Pieters,1 and Monique L. Den Boer1
1Department of Pediatric Oncology and Hematology, Erasmus Medical Center–Sophia Children’s Hospital, University Medical Center, Rotterdam, The
Netherlands; 2Department of Oncology, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, MD; and 3Department of
Pharmaceutical Sciences, St Jude Children’s Research Hospital, Memphis, TN
Treatment failure in pediatric acute lym-
phoblastic leukemia (ALL) is related to
cellular resistance to glucocorticoids (eg,
prednisolone). Recently, we demonstrated
that genes associated with glucose me-
tabolism are differentially expressed
between prednisolone-sensitive and
prednisolone-resistant precursor B-
lineage leukemic patients. Here, we show
that prednisolone resistance is associ-
ated with increased glucose consump-
tion and that inhibition of glycolysis sen-
sitizes prednisolone-resistant ALL cell
lines to glucocorticoids. Treatment of
prednisolone-resistant Jurkat and Molt4
cells with 2-deoxy-D-glucose (2-DG),
lonidamine (LND), or 3-bromopyruvate (3-
BrPA) increased the in vitro sensitivity to
glucocorticoids, while treatment of the
prednisolone-sensitive cell lines Tom-1
and RS4; 11 did not influence drug cyto-
toxicity. This sensitizing effect of the gly-
colysis inhibitors in glucocorticoid-resis-
tant ALL cells was not found for other
classes of antileukemic drugs (ie, vincris-
tine and daunorubicin). Moreover, down-
regulation of the expression of GAPDH by
RNA interference also sensitized to pred-
nisolone, comparable with treatment with
glycolytic inhibitors. Importantly, the ability
of 2-DG to reverse glucocorticoid resistance
was not limited to cell lines, but was also
observed in isolated primary ALL cells from
patients. Together, these findings indicate
the importance of the glycolytic pathway in
glucocorticoid resistance in ALL and sug-
gest that targeting glycolysis is a viable
strategy for modulating prednisolone resis-
tance in ALL. (Blood. 2009;113:2014-2021)
Introduction
Treatment of childhood acute lymphoblastic leukemia (ALL)
includes the use of several classes of chemotherapeutic agents,
including glucocorticoids (GCs), Vinca alkaloids, and anthracy-
clines. The glucocorticoids prednisolone and dexamethasone play
an essential role in essentially all therapy protocols, due to their
ability to block cell-cycle progression and induce apoptosis in ALL
cells.1-3 Although treatment of childhood ALL has greatly im-
proved over the past decades, conventional combination chemo-
therapy still fails in approximately 20% of the patients.4 Most
therapeutic failures can be explained by cellular resistance to
antileukemic drugs.5 Resistance to prednisolone at initial diagnosis
in particular is related to an unfavorable event-free survival. In
addition, in vitro prednisolone resistance is recognized as an
important negative parameter for long-term clinical outcome, even
in patients who initially have a good in vivo response to glucocorti-
coids.6-8 Therefore, it is important to find alternative therapies that
can reverse resistance toward prednisolone and dexamethasone.
Previous experiments performed in our laboratories showed that
prednisolone resistance in precursor B-ALL patients is associated
with an increased expression of genes involved in glucose metabo-
lism, suggesting that glucocorticoid resistance may be linked with
an increased rate of glycolysis.9 Glycolysis is a series of metabolic
reactions by which 1 molecule of glucose is converted to 2 mol-
ecules of pyruvate with a net gain of energy in the form of
2 molecules of ATP.10 Each reaction in the glycolytic pathway is
catalyzed by a specific enzyme, such as hexokinase (HK), phospho-
fructokinase (PFK), glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), and enolase. Under aerobic conditions, pyruvate can be
further oxidized in the mitochondria to CO2 and H2O through
oxidative phosphorylation, yielding 36 ATP molecules per mol-
ecule glucose; in the absence of oxygen, glycolysis prevails.
Cancer cells also shift their metabolism from oxidative phosphory-
lation toward the less efficient glycolysis, independent of the
presence of oxygen.11 Here, we show that an increased glycolytic
rate in ALL cells is directly related to glucocorticoid resistance and
that inhibition of glycolysis, either by the use of synthetic
compounds or by use of RNA interference, renders otherwise
resistant leukemic cells susceptible to prednisolone. Importantly,
reversal of prednisolone resistance was not limited to established
cell lines, but was also observed in primary leukemic cells of
pediatric ALL patients. These data suggest that targeting the
glycolytic pathway may be a valuable strategy to modulate
glucocorticoid resistance in the treatment of pediatric ALL.
Methods
Cell culture and lentiviral infections
Human 293T cells and Jurkat, Molt4, Tom-1, RS4;11 leukemia cell lines
were cultured at 37°C in a 5% humidified atmosphere in Dulbecco modified
Eagle medium (DMEM; 293T) or RPMI 1640 plus 10% fetal calf serum,
Submitted May 16, 2008; accepted October 4, 2008. Prepublished online as Blood
First Edition paper, October 31, 2008; DOI 10.1182/blood-2008-05-157842.
The online version of this article contains a data supplement.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked ‘‘advertisement’’ in accordance with 18 USC section 1734.
© 2009 by The American Society of Hematology
2014 BLOOD, 26 FEBRUARY 2009  VOLUME 113, NUMBER 9
 only.
For personal use at Erasmus MC Medical Library on May 25, 2011. bloodjournal.hematologylibrary.orgFrom 
100 IU/mL penicillin, 100 g/mL streptomycin, and 0.125 g/mL fungi-
zone (PSF; Invitrogen, Carlsbad, CA). Pools of early passage Jurkat
shGAPDH cells were generated by infection with lentiviral pLKO.1
Mission shRNA vectors (Sigma-Aldrich, St Louis, MO) using Retronectin
(Takara Bio, Shiga, Japan), according to the manufacturer’s instructions,
and selected in 1 g/mL puromycin.
Patient samples
Within 24 hours after sampling, mononuclear cells from bone marrow or
peripheral blood samples from untreated children at initial diagnosis of
ALL were isolated by density gradient centrifugation using Lymphoprep
(density 1.077 g/mL; Nycomed Pharma, Oslo, Norway), centrifuged at
480g for 15 minutes at room temperature. Isolated mononuclear cells were
washed twice and resuspended in RPMI 1640 medium (Dutch modifica-
tion without L-glutamine; Invitrogen), 5 g/mL insulin, 5 g/mL trans-
ferrin, 5 ng/mL sodium selenite (ITS media supplement; Sigma-
Aldrich), 100 IU/mL penicillin, 100 g/mL streptomycin, 0.125 g/mL
amphotericin B, 0.2 mg/mL gentamicin, and 20% fetal calf serum
(Invitrogen). Contaminating nonleukemic cells were removed using
immunomagnetic beads as described earlier.12 Bone marrow and periph-
eral blood samples were collected from children with newly diagnosed
ALL as approved by the institutional review board of Erasmus MC and
after written informed consent was obtained in accordance with the
Declaration of Helsinki.
In vitro MTT drug resistance assay
Responsiveness of leukemia cells to prednisolone (PRED; Bufa Pharmaceu-
tical Products, Uitgeest, The Netherlands), vincristine (VCR; TEVA
Pharma, Utrecht, The Netherlands), dexamethasone sodium phosphate
(DEX; Brocacef, Maarssen, The Netherlands), L-asparaginase (ASP;
Paronal, Christiaens, The Netherlands), and daunorubicin (DNR; Cerubid-
ine; Rhoˆne-Poulenc Rorer, Amstelveen, The Netherlands) was determined
by the 4-day in vitro 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) drug resistance assay.13 The drug concentration lethal to
50% of the ALL cells (LC50) was used as a measure of cellular drug
resistance. The final drug concentrations ranged from 24 to 15 000 g/mL
prednisolone and 1.5 to 800 g/mL dexamethasone for the prednisolone-
resistant cell lines (Jurkat and Molt4) and from 0.008 to 250 g/mL
prednisolone and 105 to 102 g/mL dexamethasone for the prednisolone-
sensitive cell lines (Tom-1 and RS4;11) and patient cells. Different
concentrations were used due to differences in glucocorticoid resistance,
but correspond with the induction of similar amounts of cell death. For
RS4;11 and Tom-1 cell lines the amount of prednisolone used corresponds
with the LC50 of in vitro good responding patients, while the amount used
for Jurkat and Molt4 corresponds with poor responders.8 The concentra-
tions of L-asparaginase, vincristine, and daunorubicin were the same for all
cell lines (0.003-10 IU/mL ASP, 0.0005-50 g/mL VCR, and 0.002-
2 g/mL DNR, respectively). Inhibition of glycolysis was established by
addition of 0.25 to 2 mM 2-deoxy-D-glucose (2-DG), 62.5 M lonidamine
(LND), or 30 M 3-bromopyruvate (3-BrPA; Sigma-Aldrich). The meta-
bolic MTT assay revealed similar results as a trypan blue exclusion assay,
which is based on cell counting (Figure S1, available on the Blood website;
see the Supplemental Materials link at the top of the online article).
Calculation of synergy
A possible synergistic effect was tested according to the criteria described
by Berenbaum in 1977.14 Briefly, a dose-response curve was constructed for
each single drug and for combinations of 2 drugs together. Equipotent drug
concentrations were then applied to the equation used by Berenbaum as
follows: [Drug Ain combination with B] / [Drug Aalone] [Drug Bin combination with A]/
[Drug Balone]. The value calculated from this formula is referred to as the
synergy factor (Fsyn), and a value less than 1 indicates synergy, Fsyn equal to
1 indicates an additive effect, and Fsyn greater than 1 an antagonistic effect
(negative synergy).
Glucose consumption assay
Glucose consumption was measured as the conversion of glucose to
6-phosphogluconate and NADH with the Glucose (HK) Assay Kit, as
described by the manufacturer (Sigma-Aldrich). Briefly, 106 leukemic cells
were grown in RPMI containing 2 g/L glucose. After 4 days, the medium
was collected by centrifugation to remove the cells, and incubated for
2 hours with glucose assay buffer, containing 1.5 mM NAD, 1 mM ATP,
1 U/mL hexokinase, and 1 U/mL glucose-6-phosphate dehydrogenase.
During this time, glucose is phosphorylated to glucose-6-phosphate.
Glucose-6-phosphate is then oxidized to 6-phospho-gluconate in the
presence of oxidized nicotinamide adenine dinucleotide (NAD), reducing
NAD to an equimolar amount of NADH. The conversion of NAD to NADH
can be measured by the increase in absorbance at 340 nm, which is directly
proportional to the glucose concentration.
RNA extraction and quantitative real-time polymerase chain
reaction
Total RNA was extracted from a minimum of 5 106 leukemic cells using
TRIzol reagent (Invitrogen) or the QIAGEN RNeasy kit (QIAGEN, Valencia,
CA) according to the manufacturer’s instructions with minor modifications.
Quantification of RNA was performed using a spectrophotometer, and cDNA
was synthesized using Superscript II, 1g total mRNA template and random
hexamers as primers (Invitrogen). Quantitative reverse transcriptase–polymerase
chain reaction (RT-PCR) analysis was performed on the Perkin-Elmer/Applied
Biosystems Prism 7700 Sequence Detection System (Foster City, CA) by
monitoring the increase of fluorescence by degradation of a Taqman probe from
double-stranded DNA. PCR primers were designed with Oligo 6.22 software
(Molecular Biology Insights, Cascade, CO) and spanned exon junctions to
prevent the amplification of any possible contaminating genomic DNA. Ribo-
somal protein S20 (RPS20) was used as a control gene for normalization. Primer
sequences are available upon request.
Results
Several genes involved in glucose metabolism were previously
identified in our laboratory as being differentially expressed in
pediatric precursor B-ALL in relation to glucocorticoid resistance.9
Microarray gene expression profiling experiments showed that
expression levels of hypoxia-inducible factor-1 alpha (HIF-1),
glucose transporter 3 (GLUT3/SLC2A3), carbonic anhydrase 4
(CA4), and glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
were significantly higher (P  .001) in prednisolone-resistant
precursor B-ALL cells compared with prednisolone-sensitive ALL
cells. To further investigate whether the glycolysis pathway is
associated with glucocorticoid resistance in ALL, several experi-
ments were carried out.
First, the glucose uptake of various prednisolone-resistant and
prednisolone-sensitive leukemic cell lines was determined. As
shown in Figure 1, the prednisolone-resistant cell lines Jurkat and
Molt4 (LC50  250 g/mL) show high glucose consumption com-
pared with the prednisolone-sensitive cell lines Tom-1 and RS4;11,
concordant with the microarray data.
Next, we investigated the response of these leukemic cell lines
to prednisolone while inhibiting the glycolysis pathway. Cells were
incubated with the glucose analog 2-DG, which competes with
glucose for transmembrane transport and is phosphorylated by
hexokinase to 2-deoxyglucose-6-phosphate. After phosphoryla-
tion, 2-DG cannot be metabolized further, leading to a proximal
blockade of glycolysis15 (Figure 2). Treatment of the cell lines
Jurkat, Molt4, RS4;11, and Tom-1 with sublethal concentrations of
2-DG, either alone or in combination with prednisolone, resulted in
a considerable reduction of glucose uptake compared with non-
treated cells (Figure 3A). This decrease in glucose consumption
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was not seen when cells were incubated with prednisolone alone.
Interestingly, the combination of 2-DG and prednisolone resulted
in markedly increased cell death in the prednisolone-resistant cell
lines Jurkat and Molt4, compared with treatment with 2-DG or
prednisolone as single drugs (Figure 3B). This synergistic effect
(Fsyn  0.61 0.05 and 0.39  0.25 for Jurkat and Molt4, respec-
tively) on cell death was not observed in the prednisolone-sensitive
cell lines RS4;11 and Tom-1 (Fsyn  0.98 0.03 and 1.05 0.04,
respectively).
2-DG acts in synergy with glucocorticoids but not with
vincristine or daunorubicin
2-DG has recently been reported to cooperate with nonglucocorti-
coid drugs in inducing cell death of several types of carcinoma
cells.16-18 To test if the observed synergism of 2-DG with pred-
nisolone in leukemic cells was specific for glucocorticoids, 2-DG
was coincubated with sublethal concentrations of the prednisolone-
analog dexamethasone or with other cytostatics that are frequently
used in the treatment of leukemia, that is, vincristine, daunorubicin,
and asparaginase. As shown in Figure 4, the antimitotic agent
vincristine or the topoisomerase II inhibitor daunorubicin did not
synergize with 2-DG in the leukemic cell lines Jurkat and Molt4; no
difference was observed in the amount of cell death between a
combination of 2-DG and these agents or treatment with 2-DG
alone. Addition of L-asparaginase in combination with 2-DG, on
the other hand, increased cytotoxicity in Molt4 cells
(Fsyn  0.67 0.07), but this synergism was not observed in Jurkat
cells. Incubation of 2-DG in combination with the glucocorticoids
prednisolone or dexamethasone, however, markedly affected cell
survival in both cell lines tested, indicating that 2-DG consistently
alters glucocorticoid resistance in these cell lines.
Inhibition of the glycolytic pathway increases
prednisolone-induced toxicity
Although the use of 2-DG as an inhibitor of glycolysis is widely
recognized, 2-DG can modulate other cellular processes as well,
such as protein glycosylation or the so-called unfolded protein
response (UPR) in the endoplasmic reticulum.19 Therefore, 2 other
compounds that inhibit glucose metabolism were tested for their
effect on prednisolone sensitivity in leukemic cell lines. Addition
of 30 M 3-BrPA20 or 62.5 M LND,21 that affect both glycolysis
and oxidative phosphorylation (Figure 2) also modulated pred-
nisolone resistance in Jurkat and Molt4 cells, but did not affect
prednisolone sensitivity in RS4;11 and Tom-1 cells, analogous to
the results of 2-DG treatment (Figure 5).
To demonstrate further that the glycolytic pathway is associ-
ated with prednisolone resistance in ALL cells, Jurkat cells were
infected with lentiviral short hairpin RNA (shRNA) plasmids to
stably silence GAPDH gene expression.22 The efficiency of
RNA interference was monitored at the RNA level by real-time
quantitative PCR (qPCR), because GAPDH is a very abundant
protein and differences in expression are difficult to detect on
Western blot. As shown in Figure 6A, RNA interference with
2 different shRNA sequences targeting GAPDH resulted in a
reduction in gene expression of approximately 60%, and
increased prednisolone sensitivity, confirming the link between
glycolysis and glucocorticoid resistance (Figure 6B). RNA
interference for another gene that was differentially regulated in
the microarray experiments, HIF-1, did not affect prednisolone
sensitivity in Jurkat cells (Figure 6C,D), suggesting that the
up-regulation of HIF-1 is not causally related to glucocorticoid
resistance in ALL.
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Figure 1. Glycolysis is up-regulated in prednisolone-
resistant human leukemia cells. Graphic representation of in
vitro prednisolone responsiveness (left panel) and glucose
consumption (right panel) of 2 prednisolone-resistant and
2 prednisolone-sensitive human ALL cell lines. Response to
prednisolone was measured by the MTT assay; glucose consumption
was calculated per cell by measuring the conversion of glucose to
6-phosphogluconate. The glucose consumption in Jurkat cells after
4 days of incubation was set to be 100%, corresponding to approxi-
mately 75% of the total glucose present in the medium (1.5 g/L). A
representative experiment is shown; data are presented as means
plus or minus SD (n 3).
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Figure 2. Schematic representation of glucose metab-
olism in mammalian cells. Glycolytic inhibitors used in
this study are indicated as 2-DG, 3-BrPA, and LND.
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2-DG increases prednisolone-induced toxicity in ALL patient
cells
The results described above clearly show that inhibition of
glycolytic metabolism increases prednisolone sensitivity in ALL
cell lines. To evaluate further the importance of this finding for
treatment of ALL patients, in vitro studies were performed on
primary leukemia cells isolated from bone marrow of patients with
newly diagnosed ALL, using the MTT assay. The effect of 2-DG on
prednisolone-induced toxicity was tested on leukemic cells of ALL
patient samples that were identified as prednisolone-resistant
(LC50  150, n 4), as intermediately resistant (LC50  0.1-150,
n  4) or sensitive to prednisolone (LC50  0.1, n 4). In concor-
dance with the cell line results, a synergistic effect was observed
between 2-DG and prednisolone in ALL cells from resistant
patients (Fsyn  0.5) and in some of the intermediately resistant
cells, but not in patients whose ALL cells were sensitive to
prednisolone (Figure 7).
Discussion
Resistance to glucocorticoids is a well recognized feature of poor
prognosis in the treatment of childhood ALL. Considering the poor
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Figure 4. Modulation of drug-resistance by 2-DG. Graphic
representation of in vitro responsiveness to cytotoxic drugs in
2 prednisolone-resistant ALL cell lines after 2-DG treatment, as
assessed by the MTT assay. Concentrations used were 1 mM
(Molt4) or 2 mM 2-DG (Jurkat), 550 g/mL prednisolone, 100 g/
mL dexamethasone, 0.5 ng/mL vincristine, and 0.0098 U/mL
L-asparaginase. Cell survival in cells treated only with 2-DG was
set at 100% to visualize the effect of synergy. Representative
experiments are shown; data are presented as means plus or
minus SD (n  3).
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Figure 3. Effect of 2-DG treatment on glucose consumption and prednisolone-
induced cytotoxicity in human ALL cell lines. Graphic representation of relative
glucose consumption (A) or in vitro prednisolone responsiveness (B) in 2 prednisolone-
resistant and 2 prednisolone-sensitive ALL cell lines after 2-DG treatment. Glucose
consumption was calculated by measuring the conversion of glucose to 6-phospho-
gluconate, and glucose consumption in Jurkat cells was set at 100%. Response to
prednisolone was measured by the MTT assay; cell survival in nontreated cells was
set at 100%. Used concentrations of prednisolone and 2-DG varied depending on
cellular toxicity (550 g/mL and 0.078 g/mL prednisolone, and 2 mM and 0.5 mM
for -resistant and -sensitive cell lines, respectively). Representative experiments are
shown; data are presented as means plus or minus SD (n  3).
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Figure 5. Effect of glycolytic inhibitors on prednisolone-induced cytotoxicity in
prednisolone–resistant and prednisolone-sensitive cell lines. Cell survival
curves representing in vitro prednisolone responsiveness, as assessed by the MTT
assay in 2 prednisolone-resistant (top panel) and 2 prednisolone-sensitive ALL cell
lines (bottom panel) after treatment with glycolytic inhibitors. Cells were treated with
1 mM (Jurkat, Molt4) or 0.5 mM 2-DG (Œ), 62.5 M LND (»), 30 M 3-BrPA (●) in
combination with prednisolone, as indicated in the figure. Cells treated only with
prednisolone served as controls (). To visualize synergy, the survival rate of
prednisolone in combination with an inhibitor was corrected for the toxicity caused by
the inhibitor itself (set to 100%). A representative experiment is shown; data are
presented as means plus or minus SD (n  3).
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prognosis of glucocorticoid resistance and the importance of
prednisolone and dexamethasone in contemporary ALL treatment
protocols, the development of strategies to reverse resistance to
these agents could have a profound impact on ALL treatment
efficacy. Several potential mechanisms for prednisolone resistance
have been studied in leukemic cell lines and ALL patients, but most
of them did not reveal clues for causes of resistance. Although the
P-glycolprotein pump (P-gp) plays a role in glucocorticoid trans-
port, we have shown previously that the efflux of glucocorticoids
by P-gp is not a significant contributor to glucocorticoid resistance
in leukemic blasts.23 In addition, the expression of the glucocorti-
coid receptor (GR) is not related to glucocorticoid resistance in
childhood ALL, and mutations in the GR are rare.24,25 Furthermore,
reduced affinity of GR for its ligand, defective translocation of GR across
the nuclear membrane, and binding of GR to the glucocorticoid-
responsive element are also not thought to be of major importance in
glucocorticoid resiststance in leukemia (reviewed by Tissing et al1 and
Haarman et al26). Here we show that leukemic cells that are resistant to
glucocorticoid treatment in vitro have increased glucose consump-
tion compared with sensitive cells, and that down-regulation of
glycolysis can attenuate glucocorticoid resistance in pediatric ALL.
It has been shown before that cancer cells, including leukemic cells,
shift their energy production from oxidative phosphorylation toward the
less efficient glycolysis pathway and catabolize glucose at a higher rate
than their nontransformed counterparts—the so-called Warburg
effect.27,28 This increased glycolysis rate is due to an up-regulation
of several genes involved in glycolysis or glucose uptake.28,29 We
observed a similarly higher expression of glycolysis-related genes
in glucocorticoid-resistant ALL cells in our previous analysis of
gene expression in primary ALL cells.9 This up-regulation in gene
expression is generally believed to be due to activation of the transcrip-
tion factors c-MYC30 or HIF-1.31,32 HIF-1 has been shown to
stimulate glucose consumption when cells are deprived of oxygen
(hypoxia) and to directly regulate the expression of genes involved in
glycolysis, including glycolytic enzymes33-35 and membrane glucose
transporters.36 However, HIF activity can also be stabilized in the
presence of oxygen, by growth factors and signal transduction routes
that also participate in carcinogenesis, including the Ras pathway.37
Interestingly, HIF-1–dependent transactivation can be stimulated by
glucocorticoids via the glucocorticoid receptor,38 providing a direct link
between glycolysis and glucocorticoids. Because HIF-1was one of the
genes with an increased expression in prednisolone-resistant ALL cells
in our microarray data, it was tempting to suggest a role for HIF-1 in the
up-regulation of glycolysis genes observed in our experiments. However,
inhibition of HIF-1 by RNA interference showed no alteration in the
sensitivity for prednisolone in Jurkat or Molt4 cell lines in vitro. This
indicates that prednisolone resistance in pediatric precursor B-ALL
patients is not due to up-regulation of HIF-1 at the transcriptional level.
Another key factor that is thought to be involved in the
regulation of glycolysis is the serine/threonine kinase PKB/Akt.39
Akt has been implicated in the regulation of glucose uptake40 and
has been shown to induce the expression of the glucose transporters
GLUT-1 and GLUT-3.41-43 Moreover, activation of Akt has been
shown to specifically activate glycolysis without affecting mitochon-
drial oxidative phosphorylation.44 Akt functions through the mam-
malian target of rapamycin (mTOR) pathway and the phosphoryla-
tion events of Akt and mTOR are thought to be rate-limiting steps
in glycolysis.45-47 Interestingly, inhibition of mTOR by rapamycin
decreased prednisolone resistance in ALL cell lines,48 suggesting
the involvement of the Akt/mTOR pathway in glucocorticoid
resistance in pediatric ALL. A role for Akt in glucocorticoid
resistance is even more plausible if one thinks about its function in
cell survival. Akt has been shown to promote mitochondrial
integrity and inhibit cytochrome c release, thereby preventing
apoptosis.49 Importantly, Akt requires the presence of glucose to
exert its antiapoptotic function,50 stressing once more the impor-
tance of the glycolysis pathway as a target for cancer treatment.
Given that cancer cells have higher glycolytic rates than their
nontransformed counterparts, inhibition of glycolysis more specifically
affects tumor cells and has little or no effect on normal cells.51 Inhibition
of glycolysis by 2-DG but not inhibition of the oxidative phosphoryla-
tion process was shown to reduce the viability of the PER-427 T-ALL
cell line, pointing to glycolysis as potential therapeutic target.28 Here, we
show that disruption of the glycolytic pathway specifically affects
prednisolone-resistant leukemia cells with high metabolic activity, while
no sensitizing effect is observed in cells already sensitive to pred-
nisolone. This synergistic effect is independent of the glycolytic
inhibitor used: addition of 2-DG, 3-BrPA, or LND all rendered
otherwise resistant leukemia cells more susceptible to prednisolone.
Moreover, down-regulation of GAPDH by use of RNAinterference also
modulated prednisolone sensitivity, confirming a direct link between
glucocorticoid resistance and glucose metabolism. Because the sensitiz-
ing effect of glycolytic inhibitors on prednisolone resistance was not
only observed in ALL cell lines but also in primary cells of pediatric
ALL patients, interference with the glycolysis pathway seems a promis-
ing way to reverse glucocorticoid resistance in childhood leukemia.
In past years, targeting glycolysis has become increasingly more
attractive as a therapeutic approach for several kinds of tumors.52,53
However, short-term inhibition of glycolysis alone appears not to be
sufficient to produce significant antitumor effects in vivo. Some of the
compounds that are used to block glucose metabolism, such as 3-BrPA,
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Figure 6. Inhibition of GAPDH expression by RNA interference increases
prednisolone-induced cytotoxicity. (A) mRNA levels of GAPDH in Jurkat cells as
measured by qPCR. Two different shRNA sequences targeting GAPDH were used
(shGAPDH-1 and -2). Expression of cells infected with nonsilencing shRNA se-
quences was set at 100% and relative expression levels were calculated. (B) Cell
survival curves representing in vitro prednisolone responsiveness after RNA interfer-
ence in cells interfered for GAPDH (», Œ) or in cells infected with a nonsilencing
shRNA sequence (). (C) mRNA levels of HIF-1 in Jurkat cells as measured by
qPCR. Two different shRNA sequences targeting HIF-1were used (sh HIF-1-1 and
-2). Expression of cells infected with nonsilencing shRNA sequences was set at
100%, and relative expression levels were calculated. (D) Cell survival curves
representing in vitro prednisolone responsiveness after RNA interference in cells
interfered for HIF-1 (», Œ) or in cells infected with a nonsilencing shRNA sequence
(). A representative experiment is shown; data are presented as means plus or
minus SD (n  3).
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are relatively unstable and show significant inhibition of glycolysis only
at relatively high concentrations.54 Similarly, the dose of LND necessary
to achieve clinical efficacy is associated with toxicity, limiting the use of
these compounds as primary therapy.51 Instead, the use of glycolysis
inhibitors in combination with other agents appears to be a more
promising approach. Glycolytic inhibitors have been reported to in-
crease the cytotoxicity of other agents, possibly by reducing the cell’s
ability to repair damage caused by those agents or by increasing the
permeability of tumor cells. Addition of LND, for example, has been
shown to result in a significant increase in the intracellular concentra-
tions of doxorubicin.55 Moreover, LND has been shown to increase the
efficacy of cisplatin, doxorubicin, and melphalan both in vitro and in
vivo.56,57 Similarly, the addition of 3-BrPA was found to increase the
cytotoxic effect of doxorubicin, vincristine, and Ara-C in HL-60/AR
cells,54 and the concurrent administration of 2-DG increased the in vivo
efficacy of both doxorubicin and paclitaxel in osteosarcoma and
non–small cell lung cancer xenografts.51 In our experiments the
coincubation of 2-DG did not increase the cytotoxicity of vincristine or
daunorubicin in leukemia cells, while it sensitized toward both pred-
nisolone and dexamethasone, suggesting that 2-DG particularly inter-
feres with glucocorticoid action in ALL. Recently, clinical trials have
been performed using glycolytic inhibitors in breast cancer, ovarian
cancer, lung cancer, and malignant glioma,52,58,59 and a phase 1/2 trial is
currently ongoing for prostate cancer, administering 30 mg/kg (	0.2
mM) 2-DG on a daily schedule for 2 weeks60 (www.clinicaltrials.gov,
trial NCT00633087). Moreover, clinical evaluation in brain tumor
patients showed that 2-DG is safe to use at doses up to 250 mg/kg body
weight (	1.5 mM) given weekly for 7 weeks.61 This implies that the
concentrations of 2-DG used in our in vitro experiments are also
applicable in clinical practice. Together, the results presented here point
to the importance of the glycolytic pathway in glucocorticoid resistance
and suggest that targeting this pathway may be a particularly promising
approach to reverse prednisolone resistance in pediatric ALL in patients
for whom currently alternative treatment protocols are less successful,
for example, patients suffering from a second or later relapse.
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